as per annexure enclosed
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong full-year results for FY2025-26 ending March 31, 2026. Consolidated revenue grew 15.8% to Rs 252,285 million, while consolidated PAT surged 33.1% to Rs 20,027 million, driven by healthcare services and digital health/pharmacy segments. Basic EPS on consolidated basis rose to Rs 135.04 from Rs 100.56. EBITDA margin expanded to 10.4% from 9.4% YoY. The Board declared a final dividend of Rs 10 per share (200%) and approved an interim dividend of Rs 10 already paid. Key corporate actions include: a composite scheme to demerge the pharmacy distribution and digital health platform into Apollo Healthtech Limited; merger of wholly-owned subsidiary Apollo Hospitals North Limited into the parent; and a transaction where Apollo Health and Lifestyle Limited will divest certain fertility/hospital assets to Kids Clinic India Limited (Cloudnine) for Rs 15,500 million (cash + equity). Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion. The company holds ICRA AAA and CRISIL AA+ credit ratings.
Apollo Hospitals delivered robust growth with PAT up 33% and margin expansion, signaling strong operational performance. The upcoming demerger and Cloudnine transaction could unlock value in the pharmacy/digital segment. The Karnataka land grant dispute remains a contingent liability risk.